Biotech has issued a statement on the phase 3 trial data that says the test result will be made public in July. Before data submission, it is mandatory to get approval from the WHO emergency listing ( EUL). A Debate has been going in the medical archive, a group of doctors who conducted a study on both the vaccines saying that antibodies can be seen in people who are taking covidsheild instead of covaxin. After this, the Bharat Biotech manufactures of Covaxin have said those studies had a lot of flaws and that the pan-India study was not a peer-reviewed study.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting